Mammalian Cell Fermentation Technology Market Report 2026

The mammalian cell fermentation technology market size has grown rapidly in recent years. It will grow from $57.37 billion in 2025 to $64.07 billion in 2026 at a compound annual growth rate (CAGR) of 11.7%. The growth in the historic period can be attributed to growth of monoclonal antibody therapeutics, early success of mammalian cell expression systems, increasing biopharmaceutical approvals, reliance on batch-based fermentation processes, expansion of academic research in cell culture technologies.

The mammalian cell fermentation technology market size is expected to see rapid growth in the next few years. It will grow to $94.89 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to rising demand for biologics and biosimilars, increasing investment in cell line engineering, growth of personalized medicine, expanding vaccine development pipelines, increasing biomanufacturing capacity in emerging markets. Major trends in the forecast period include increasing adoption of cho cell-based production platforms, rising demand for high-yield and scalable bioprocessing, growing outsourcing to cdmos for biologic manufacturing, expansion of single-use and modular bioreactor systems, higher focus on process optimization and yield consistency.

The increasing demand for biologics is expected to drive the growth of the mammalian cell fermentation technology market in the coming years. Biologics are therapeutic products derived from living organisms or their components, commonly used to treat conditions such as cancer, autoimmune disorders, and infectious diseases. This rising demand is supported by advancements in biotechnology, the proven effectiveness of biologics in managing prevalent chronic diseases, regulatory approvals, and increasing investment in research and development. Mammalian cell fermentation technology enables efficient production of complex biologics, addressing the need for personalized and targeted therapies. Its scalability, versatility, and capacity to produce high-quality proteins foster innovation within the biopharmaceutical sector. For example, in February 2024, according to the National Library of Medicine, a US-based medical library, the Food and Drug Administration (FDA) approved 55 new drugs in 2023, including 29 new chemical entities (NCEs) and 25 new biological entities (NBEs), representing a 50% increase compared to 37 approvals in 2022. Consequently, the rising demand for biologics is also propelling the growth of the bacterial cell fermentation technology market.

Major companies operating in the mammalian cell fermentation technology market are concentrating on developing innovative solutions, such as mammalian cell culture, to enhance their market position. Mammalian cell culture is an essential tool across various sectors, including biomanufacturing, research, and regenerative medicine, as it facilitates the production of therapeutic proteins, vaccines, and functional cells or tissue analogs. For example, in June 2024, Syntegon, a Germany-based biotechnology company, introduced its new Modular Bioprocessing Platform (MBP) at Achema 2024, aimed at addressing key challenges in biopharmaceutical production. This innovative platform provides a highly flexible, fully integrated, and automated solution suitable for multiple applications, including microbial and mammalian cell cultures, proteins, peptides, oligonucleotides, plasmid DNA, and recombinant vaccines. The MBP's modular design enables shorter lead times and lower costs while maintaining high functionality and quality, following the "made in Germany" standard. Its prefabricated cleanroom setup positions all peripheral technology outside the cleanroom, improving efficiency and simplifying maintenance.

In February 2024, Chrysea Limited, an Ireland-based biotechnology company, acquired Rodon Biologics from Iberfar Group for an undisclosed amount. Through this acquisition, Chrysea aims to enhance its synthetic biology and biopharmaceutical development capabilities by incorporating Rodon Biologics' expertise in protein engineering, cell-line development, precision fermentation, downstream processing, formulation, analytics, and production. Rodon Biologics, based in Portugal, manufactures biological products and specializes in mammalian cell fermentation technology.

Major companies operating in the mammalian cell fermentation technology market are AbbVie Inc., Thermo Fisher Scientific Inc, AstraZeneca PLC, Roche Holdings Inc., Merck KGaA, AGC Group, Lonza Group Ltd., Boehringer Ingelheim GmbH, Catalent Inc., Sartorius AG, Samsung Biologics Co. Ltd., WuXi Biologics, Biocon Limited, Eppendorf AG, KBI Biopharma Inc., Fujifilm Diosynth Biotechnologies, Avid Bioservices Inc., BiOZEEN, Nordmark Pharma GmbH, Scorpius BioManufacturing Inc.

North America was the largest region in the mammalian cell fermentation technology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mammalian cell fermentation technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the mammalian cell fermentation technology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the mammalian cell fermentation technology market by increasing costs for imported bioreactors, cell culture media, and specialized fermentation equipment. Biopharmaceutical manufacturing segments and cdmos are most affected, particularly in regions dependent on imported bioprocessing components such as asia-pacific and parts of europe. These added costs may raise overall production expenses and slow capacity expansion. However, tariffs have encouraged local sourcing and domestic manufacturing of fermentation equipment, supporting long-term supply chain resilience.

The mammalian cell fermentation technology market research report is one of a series of new reports that provides mammalian cell fermentation technology market statistics, including mammalian cell fermentation technology industry global market size, regional shares, competitors with a mammalian cell fermentation technology market share, detailed mammalian cell fermentation technology market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell fermentation technology industry. This mammalian cell fermentation technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mammalian cell fermentation technology is the process of cultivating mammalian cells under controlled conditions to produce biopharmaceuticals, vaccines, or other biological products. This process involves optimizing cell growth and protein expression in bioreactors or fermenters to ensure high-quality and consistent production of the desired therapeutic proteins or substances.

The main types of mammalian cell fermentation technology include Chinese hamster ovary cell fermentation, human embryonic kidney cell fermentation, baby hamster kidney cell fermentation, murine myeloma cell fermentation, and other types. Chinese hamster ovary cell fermentation is a biotechnological method used for producing therapeutic proteins, such as monoclonal antibodies and recombinant proteins. Its applications include monoclonal antibodies, recombinant proteins, vaccines, hormones, enzymes, and other uses, serving various end-users such as biopharmaceutical companies, contract research organizations, contract development and manufacturing organizations, and academic and research institutes.

The mammalian cell fermentation technology market consists revenues earned by entities by providing services such as cell line development, process development, cell culture and fermentation, analytical and quality control services, and formulation and fill-finish services. The market value includes the value of related goods sold by the service provider or included within the service offering. The mammalian cell fermentation technology market also includes of sales of biosimilars, cell and gene therapy products, diagnostic enzymes and proteins, and therapeutic proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.